FENNEC PHARMACEUTICALS INC.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $44.6M | $47.5M | $21.3M | $1.5M | — | $170.0K | $0 |
| Cost of Revenue | — | — | — | $1.3M | $86.0K | — | — | — |
| Gross Profit | — | — | — | $20.0M | $1.4M | — | — | — |
| Gross Margin | — | — | — | 94.1% | 94.4% | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | $250.0K | $307.0K | $56.0K | $3.5M | $5.0M | $5.1M | $5.6M |
| SG&A Expense | — | $28.3M | $23.1M | $20.6M | $17.7M | $12.2M | $13.0M | $7.4M |
| Operating Income | — | $-6.3M | $2.6M | $-12.8M | $-22.6M | $-17.2M | $-17.9M | $-13.0M |
| Operating Margin | — | -14.1% | 5.4% | -60.1% | -1,471.6% | — | -10,520.6% | — |
| Interest Expense | — | $2.1M | $4.1M | $3.4M | — | — | — | — |
| Pretax Income | — | $-9.6M | $-71.0K | $-16.0M | — | — | — | — |
| Income Tax Expense | — | $106.0K | $365.0K | — | $0 | $0 | $0 | $0 |
| Net Income | — | $-9.7M | $-436.0K | $-16.0M | $-23.7M | $-17.3M | $-18.1M | $-12.8M |
| Net Margin | — | -21.8% | -0.9% | -75.5% | -1,544.9% | — | -10,652.4% | — |
| EPS (Basic) | — | $-0.34 | $-0.02 | $-0.60 | $-0.90 | $-0.67 | $-0.76 | $-0.64 |
| EPS (Diluted) | — | $-0.34 | $-0.02 | $-0.60 | $-0.90 | $-0.67 | $-0.76 | $-0.64 |
| Shares Outstanding (Basic) | 34.5M | 28.6M | 27.3M | 26.6M | 26.3M | 26.0M | 23.7M | 19.9M |
| Shares Outstanding (Diluted) | 34.5M | 28.6M | 27.3M | 26.6M | 26.3M | 26.0M | 23.7M | 19.9M |
| Dividends Per Share | — | — | — | — | — | — | — | — |